Option chain shows key data for Vincerx Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Vincerx Pharma.

Vincerx Pharma (NASDAQ:VINC) Stock, Option Chain

Vincerx Pharma

Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.

laboratory-563423_1920

Biotech

News

Health Care

Movers

Trading Ideas

General

VINC

Vincerx Pharma announces early results for VIP943 and VIP236 in Phase 1 studies targeting hard-to-treat cancers, with complete responses seen in AML and HR-MDS patients and encouraging disease control rates in solid tumors.

Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates

Aon - logo

Intraday Update

Markets

ACCD

ACMR

ACON

AILE

AIRE

ALSN

APPF

ARCB

ATXI

BACK

BDRX

CGEM

CSSE

DXCM

ELWS

EXPO

FCUV

FRGT

GOOG

GOOGL

ICLK

INTC

KNSL

KTOS

Kintara Therapeutics, Inc. - Common Stock

KTRA

Eaton Vance Massachusetts Municipal Income Trust

NIVF

NUWE

NWGL

ODFL

PCSA

PEGY

RERE

ROKU

SAIA

SBFM

SGBX

SKIL

SLCA

SNAP

TEAM

TNET

TVGN

WORX

ZVSA

Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Vincerx Pharma shares are trading lower by 9.7% to $0.81 during Friday&#39;s session. The company priced an underwritten public offering.

Why Vincerx Pharma (VINC) Stock Is Falling

Vincerx Pharma Inc

VINchain

Vince Holding Corp

Vinci Partners Investments Ltd. - Class A Common Shares

Vinci Partners Investments Ltd

Vinci SA

VINCO VENTURES INC by Vinco Ventures, Inc.

Vinco Ventures Inc

WIIM

SOUN

SoundHound AI shares are trading higher. The company announced its Amelia AI agents have supported the handling of 100,000 customer calls for Apivia Courtage and reduced the number of inbound queries handled directly by a customer relations team by nearly 20%.

Raymond James analyst Daniel Tamayo maintains F N B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>) with a Outperform and raises the price target from $17 to $19.

Price Target

Analyst Ratings

Raymond James Maintains Outperform on F N B, Raises Price Target to $19

TD Cowen analyst Ritu Baral maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and lowers the price target from $10 to $9.

SAGE

TD Cowen Maintains Hold on Sage Therapeutics, Lowers Price Target to $9

OKLO

Oklo shares are trading higher. The stock may be moving in response to its acquisition target Atomic Alchemy which signed an MOU with Zeno Power to provide fuel for commercial radioisotope power systems.

Raymond James analyst John Freeman maintains Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) with a Strong Buy and raises the price target from $77 to $78.

Raymond James Maintains Strong Buy on Occidental Petroleum, Raises Price Target to $78

When <a href="https://www.benzinga.com/personal-finance/24/09/40922368/excuse-me-you-want-to-check-my-credit-nba-legend-shaq-shares-he-felt-disrespected-when-trying-to">Shaquille O'Neal</a> got drafted in 1992, he didn't just sign a basketball contract; he essentially handed his parents a life-changing upgrade.&nbsp;
Raised by <a href="https://www.benzinga.com/personal-finance/24/10/41337452/nba-legend-shaq-was-raised-by-teen-mom-who-fueled-his-success-cant-outplay-me-because-if-you-are">parents who instilled discipline</a> and a strong work ethic, Shaq didn't forget where he came from – or the sacrifices his family made to get him to the top. But instead of writing them a one-time check, Shaq had a better idea: he put them on the payroll. Yes, he turned "family support" into a literal job title with serious perks.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/advisor-adv-warren-buffett">Warren Buffett Flipped His Neighbor's $67,000 Life Savings Into A $50 Million Fortune — This Would Be Worth Over $500 Million Today</a></li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
</ul>
During a 2022 interview on Drink Champs, Shaq explained how he started managing his finances after reading The Dummies' Guide to Starting Your Own Business. That book didn't just teach him about incorporating himself as a business – it shaped his financial playbook. He made moves as soon as the ink dried on his first NBA contract.
"The first thing I did was incorporate ‘Shaq,' and then I put my mom on salary and put my dad on salary," Shaq shared. His stepfather, Phillip Harrison, a military veteran earning $60,000 a year, got a raise that would make anyone emotional. "I asked him, ‘How much you make in the Army?' He said, ‘I only make $60,000.' [I told him], ‘Now you making half a million a year.' He started crying."
And Shaq didn't stop there. He asked his mom how much she wanted to make and, in classic Shaq fashion, gave her a hefty $750,000 salary.
Trending: This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai-2"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before it closes TONIGHT.</a>
But Shaq wasn't just handing out big checks without a plan. He emphasized teaching his parents how to manage their new responsibilities. "I also had to teach them the business," he said. By putting his parents on payroll and teaching them how it all worked, he turned what could've been a financial free-for-all into a sustainable family structure.
Shaq credits much of his financial savvy to self-education. "I learned about business not from college, but from a book," he explained, urging others to take control of their learning. "Whatever you want to do, educate yourself." Reflecting on how far access to information has come, he added, "If I was 14 or 15 now, I'd be a genius because information is so available now." He's right – today, anyone can tap into a world of resources through the internet, YouTube tutorials and forums.
Putting his parents on the payroll wasn't just about <a href="https://www.benzinga.com/personal-finance/24/11/41869301/shaqs-got-a-500-million-fortune-but-his-kids-arent-getting-a-dime-without-earning-it-you-need-3-degrees-to-touch-daddys-cheese">sharing his wealth</a> but about teaching them responsibility and business skills. Shaq made it clear that their new roles came with expectations. "I also had to teach them the business," he said. They weren't just handed checks; they became real employees with structured salaries.&nbsp;
Trending: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
This thoughtful setup not only empowered his parents but also had financial benefits. As one of the hosts pointed out, "Instead of giving it to the IRS, you're giving it to your family and you can write it off." It was a win-win, highlighting Shaq's practical, forward-thinking approach to money.
O'Neal's story highlights a valuable lesson: wealth isn't just about making money; it's about managing it wisely and bringing others along for the ride. From incorporating his brand to employing his family, Shaq's approach is a master class in turning success into a legacy.
Shaq's savvy business moves – like owning restaurants and investments in Vegas – have made him one of the <a href="https://www.benzinga.com/personal-finance/24/08/40658562/nba-legend-shaq-tells-his-kids-in-order-to-get-my-cheese-you-have-to-present-me-with-two-degrees">wealthiest athletes in history</a>. But at the heart of it all? A guy who just wanted to make his parents proud.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

NBA Legend Shaq Put His Mom and Dad On Payroll When He Made It Big In Basketball – 'Now You Making Half A Million A Year'

Raymond James analyst John Freeman maintains Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) with a Strong Buy and raises the price target from $34 to $44.

Raymond James Maintains Strong Buy on Antero Resources, Raises Price Target to $44

BCTX

BriaCell Therapeutics shares are trading higher after the company announced it dosed the first patient in its Phase 1/2 study of Bria-OTS.

KKR shares are trading higher after the company announced n approximately $370 million growth investment in Lighthouse.

Raymond James analyst Brian Gesuale initiates coverage on Amentum Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTM#NYSE">AMTM</a>) with a Outperform rating and announces Price Target of $30.

Initiation

AMTM

Raymond James Initiates Coverage On Amentum Holdings with Outperform Rating, Announces Price Target of $30

Starbucks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) is evaluating options for its Chinese operations, including the potential sale of a stake in the business.
The coffee chain has consulted advisers on strategies to expand in China and has gauged interest from potential investors, including local private equity firms, Bloomberg cites familiar <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-11-21/starbucks-is-said-to-consider-selling-stake-in-chinese-business?sref=TBDibEcD" rel="noreferrer noopener">sources</a>. Possible buyers include Chinese conglomerates or regional companies with relevant industry expertise.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42109965/baidus-q3-earnings-revenue-slides-weak-online-ads-market-impact-margins" rel="noreferrer noopener">Baidu&#8217;s Q3 Earnings: Revenue Slides, Weak Online Ads Market Impact Margins</a>
Starbucks is seeking strategic partnerships in China as it grapples with declining sales in the region. Once its fastest-growing market, China now faces economic headwinds, including a property slump, employment uncertainties, and slower consumer spending, SCMP <a target="_blank" href="https://www.scmp.com/business/companies/article/3287574/starbucks-seeks-strategic-partnership-find-perk-china-amid-brewing-price-war?module=perpetual_scroll_0&amp;pgtype=article" rel="noreferrer noopener">reports</a>.
The company faces mounting pressure from activist investor Elliott Investment Management, which has urged a review of its Chinese business. Other Western brands have made similar moves, such as McDonald&#8217;s Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) and Yum! Brands Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>), which sold stakes in their Chinese operations to private equity investors to drive growth and adapt to local market demands.
China, Starbucks&#8217; second-largest market, generated approximately $3 billion in revenue last year, with the store count increasing by 12%. Despite this growth, Starbucks is contending with stiff competition from local rivals like Luckin Coffee Inc, which has rapidly gained market share with more affordable offerings.
Starbucks saw its same-store sales in China shrink by 14% in the fiscal fourth quarter ending September, surpassing its global sales decline of 9%.
Rising competition from cost-effective rivals such as Luckin Coffee and Cotti Coffee has further strained its position, as these companies attract budget-conscious consumers with significantly lower-priced offerings.
Brian Niccol, who became CEO in August 2024, acknowledged the challenges, citing an &#8220;extreme&#8221; competitive environment and macroeconomic pressures.
Starbucks&#8217; signature 27-yuan ($3.70) Americano is losing traction against Luckin Coffee&#8217;s brews, priced at 11.9 yuan, and Cotti Coffee&#8217;s offerings, which initially cost 9.9 yuan before a modest price hike to reduce cash burn.
Cotti Coffee, founded by two former Luckin executives in 2022, has rapidly expanded to 10,000 locations across 28 markets, creating intense competition in China&#8217;s coffee industry.
Meanwhile, Starbucks operated 7,596 stores in China as of September, accounting for 19% of its global footprint.
Starbucks is also contending with the growing popularity of fruit-infused teas and juices, which is increasing competition for consumer spending.
In October, TD Cowen analyst Andrew M. Charles <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41661427/starbucks-faces-sales-slump-but-analysts-see-silver-lining-with-new-ceos-efficiency" rel="noreferrer noopener">reiterated a Buy rating</a> on Starbucks with a price target of $110, emphasizing its potential for over 5% same-store sales growth in North America but noted delays in menu innovation due to SKU simplification efforts.
Wedbush analyst Nick Setyan maintained a Neutral rating for Starbucks but reduced the price target to $95, citing limited near-term visibility on revenue and earnings. Setyan highlighted CEO Brian Niccol&#8217;s focus on reducing wait times to under four minutes while maintaining the coffeehouse experience as a critical improvement. The company plans to eliminate alternative dairy upcharges, impacting U.S. margins by 1%, and will reduce promotional offers, prioritizing marketing efforts and store remodels.
Price Action: SBUX stock is up 1.57% at $99.80 at last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42098028/qualcomms-shift-from-handsets-to-ai-and-automotive-wins-analysts-confidence" target="_blank" rel="noreferrer noopener">Qualcomm&#8217;s Shift From Handsets To AI And Automotive Wins Analysts&#8217; Confidence</a></li>
</ul>
Photo via Shutterstock

Asset Sales

Media

SBUX

Starbucks Eyes Stake Sale in China Amid Fierce Competition and Falling Sales

Piedmont Lithium shares are trading higher after Macquarie upgraded the stock from Underperform to Neutral and announced a price target of $13.5.

TD Cowen analyst Oliver Chen maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Hold and lowers the price target from $165 to $145.

TD Cowen Maintains Hold on Target, Lowers Price Target to $145

SURG

SurgePays shares are trading higher after announcing an agreement with AT&T that enables the company to offer mobile wireless, voice, data, and messaging services.

SurgePays, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>) shares are trading higher after the company inked a deal with AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) to provide mobile wireless, voice, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42110967/surgepays-establishes-strategic-agreement-with-at-t" rel="noreferrer noopener">data, and messaging services</a>.
As per a multi-year mobile virtual network operator (MVNO) agreement, SurgePays will offer its customers reliable 4G LTE and 5G services using AT&amp;T&#8217;s wireless network, which covers over 99% of Americans in North America.
The AT&amp;T agreement enables SurgePays to empower other businesses to deliver MVNO wireless services while expanding into underserved and rural markets. Leveraging its vast network of convenience stores, bodegas, and neighborhood locations, SurgePays ensures easy access to prepaid wireless and financial products.
Brian Cox, Chairman and CEO, said, &#8220;Once service integration with AT&amp;T is complete, we will be able to provide services on a network that our customers can depend on to stay securely connected, whether they are existing SurgePays customers or new ones coming to us through our convenience store distribution channel, operation centers or online.&#8221;
&#8220;Back in July, we announced the hiring and appointment of&nbsp;Joseph Gomez&nbsp;as vice president of MVNO Operations,&#8221; added Cox. &#8220;Joe had served AT&amp;T for decades leading strategic initiatives, developing partnerships and overseeing national sales and distribution channels. He has wasted no time in following through on his charge of driving our MVNO strategy with a focus on market share growth.&#8221;
Price Action: SURG shares are up 17.1% at $1.71 at the last check Thursday.
Image sourced from Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42116183" target="_blank" rel="noreferrer noopener">Michael Saylor Predicted Bitcoin To Hit $13 Million — If It Happens, It Will Entail &#8216;Massive Hyperinflation,&#8217; Analyst Warns</a></li>
</ul>

Equities

Contracts

Small Cap

SurgePays Teams Up With AT&T For Affordable Wireless Solutions Nationwide; Stock Gains

At the <a href="https://cannabismarketspotlight.com/california/anaheim-november-12/">Cannabis Market Spotlight: California</a> event in Anaheim, Lisa Weser, founder and CEO of Trailblaze, addressed a core debate within the cannabis industry: balancing consumer-driven product trends with a commitment to quality production. 
Weser, alongside other industry professionals, shared insights on how cannabis brands can adapt to shifting consumer preferences while remaining true to high production standards.
<h3 class="wp-block-heading">Consumer Demand or Industry Direction?</h3>
Weser's panel tackled a foundational question: are consumer preferences driving changes in the cannabis industry, or is the industry itself setting expectations? Speaking with experts from Papa &amp; Barkley, Jetty Extracts, Natura, and Timeless Vapes, Weser observed that perspectives on this issue vary widely.
See Also: <a href="https://www.benzinga.com/news/events/24/11/42115223/tax-woes-hemp-rules-california-cannabis-authority-nicole-elliott">From Tax Woes To Hemp Rules: Department Of Cannabis Control&#8217;s Nicole Elliott Outlines Regulatory Goals</a>
One common theme in the discussion was the need to "meet consumers where they are," a concept familiar in the consumer goods space. This approach focuses on crafting products that appeal directly to consumers' tastes. 
"We're seeing new consumers, especially younger ones, drawn to products with bold flavors," Weser said, noting the appeal of flavor-centric offerings over traditional high-grade cannabis flowers for some segments of the market.
<h3 class="wp-block-heading">Back to Basics: Quality First</h3>
In contrast, other panelists argued for a renewed focus on quality in cannabis production. They expressed concern that while consumer trends are essential, some brands may have strayed too far from the core values of cultivating excellent cannabis. According to Weser, many industry leaders believe that true product quality "starts at the farm," emphasizing that the cannabis industry should prioritize strong cultivation practices rather than relying solely on novelty.
This quality-focused viewpoint suggests that long-term success may be achieved by building on reliable practices, producing products that satisfy discerning customers, and reinforcing brand integrity.
<h3 class="wp-block-heading">Striking a Balance</h3>
Weser highlighted that both approaches hold weight in today's diverse cannabis market. Flavor-driven products may help engage newer consumers while focusing on quality that resonates with established users. "Both approaches are valid in today's market," she remarked, underscoring the importance of accommodating the varied needs of cannabis consumers.
This dialogue reflects a larger conversation in the cannabis industry about balancing the drive to meet consumer preferences with a dedication to sustainable quality. By exploring these perspectives, Weser's panel provided valuable takeaways on how brands can connect with different customer bases while maintaining high standards.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42111795/californias-cannabis-future-why-one-expert-believes-the-market-will-hold-strong" target="_blank" rel="noreferrer noopener">California's Cannabis Future: Why One Expert Believes The Market Will Hold Strong</a></li>
</ul>
Image: AI-Generated Image

Cannabis

Events

Exclusives

Interview

'Innovation Starts At The Farm': How Cannabis Brands Balance Quality With Consumer Demand

GE Vernova shares are trading higher after Wells Fargo initiated coverage on the stock with an Overweight rating and announced a $385 price target.

AMZN

Amazon shares are trading lower following a report suggesting the company is likely to be investigated under the EU's Digital Markets Act next year.

The Container Store shares are trading lower after the company announced it expects the conditions of the sales and purchase agreement (SPA) with Beyond Inc to remain unsatisfied.

Mizuho analyst Gregg Moskowitz maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Outperform and raises the price target from $165 to $195.

SNOW

Mizuho Maintains Outperform on Snowflake, Raises Price Target to $195

Vincerx Pharma GAAP EPS of -$0.05

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vincerx Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/vinc-stock-quote/">VINC</a>) just reported results for the second quarter of 2024.<ul><li>Vincerx Pharma reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -20 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vinc-stock-earnings-vincerx-pharma-for-q2-of-2024/">VINC Stock Earnings: Vincerx Pharma Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VINC Stock Earnings: Vincerx Pharma Beats EPS for Q2 2024

Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Vincerx Pharma Inc (VINC – Research Report) on August 9 and set a price target o...

Buy Rating Affirmed for Vincerx Pharma Amid Positive Clinical Progress and Stable Financial Outlook

Vincerx Pharma Inc (VINC) has shared an update. Vincerx Pharma, Inc. has implemented a one-time stock option repricing and exchange program, effect...

Vincerx Pharma Announces Stock Option Repricing and Shareholder Approval

Jonathan Chang, an analyst from Leerink Partners, maintained the Buy rating on Vincerx Pharma Inc (VINC – Research Report). The associated price ta...

Vincerx Pharma: A Strong Buy on Promising VIP943 Clinical Results and Strategic Focus

Vincerx stock tumbles 20% on corporate updates

"As we direct our efforts and resources toward our ADC technologies and programs, we are committed to advancing VIP943 based on the encouraging saf...

Vincerx Pharma reports Q3 EPS (17c), consensus (22c)

Vincerx Pharma GAAP EPS of -$0.17

Vincerx Pharma Inc ( ($VINC) ) has released its Q3 earnings. Here is a breakdown of the information Vincerx Pharma Inc presented to its investors. ...

Vincerx Pharma Reports Q3 2024 Financial Results

Jonathan Chang, an analyst from Leerink Partners, reiterated the Buy rating on Vincerx Pharma Inc (VINC – Research Report). The associated price ta...

Vincerx Pharma Inc: Strategic Advancements and Promising Pipeline Highlight Buy Rating

Earnings

Press Releases

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024

Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)

Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants

Financing

Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants

Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Vincerx Pharma Reports Second Quarter 2024 Financial Results

Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates

Comments

Vincerx Pharma

Vincerx Pharma (VINC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga